Sanofi/Regeneron’s Libtayo shows benefit in BCC
BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note
Read More
Tag: cemiplimab
NICE approves CDF funding for Sanofi’s Libtayo
Around 560 patients per year with cutaneous squamous cell carcinoma are thought to be eligible for treatment with the drug in England
Read More
Libtayo bags EU approval for skin cancer
The European Commission has granted conditional marketing authorisation for the drug for patients who are not candidates for curative surgery or curative radiation.
Read More
US OKs Sanofi, Regeneron’s new skin cancer immunotherapy
Sanofi and Regeneron’s imunotherapy Libtayo has been cleared in the US to treat patients with certain forms of cutaneous squamous cell carcinoma (CSCC).
Read More
US priority review for Sanofi, Regeneron’s cemiplimab
US regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC), or those with locally advanced CSCC who are not candidates for surgery.
Read More
EU reviews for Sanofi’s Dupixent, cemiplimab
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Read More
Sanofi, Regeneron beef up investment in immunotherapies
Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.
Read More
Sanofi, Regeneron ready to file cemiplimab
Sanofi and Regeneron are gearing up to file their experimental PD-1 inhibitor cemiplimab on both sides of the Atlantic following the drug’s success in clinical trials.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
